PHARMeMED · The industry in context

Discover what’s next in pharma, biotech and medtech.

Important news, emerging therapies and professional opportunities, all in one place.

Biopharma Markets

Market data may be delayed.

Lead News

24 Sep 2026

Precision Neuroscience raises $250m for brain-computer interface expansion

Precision Neuroscience has raised $250 million in an oversubscribed Series D financing that will support expansion of its clinical brain-computer interface programme, further regulatory work and preparations for commercialisation. The New York-based neurotechnology company announced the financing on 24 September 2026. The round was co-led by Pershing Square Inc., the Ackman Oxman Institute and an undisclosed life-sciences investment fund, and brings Precision’s total capital raised since its founding in 2021 to approximately $430 million. The financing…

Medtronic

Read article

Latest Intelligence

Clinical Development

OSE delays ARTEMIA futility analysis as events accrue more slowly than expected

Announcement 28 Sep 2026 · 06:30:00 London (BST)

Published 28 Sep 2026 · 14:22:31 London (BST)
Clinical Development

Akeso begins global Phase III cadonilimab head-to-head trial against nivolumab in gastric cancer

Announcement 28 Sep 2026 · 03:05:00 London (BST)

Published 28 Sep 2026 · 14:22:31 London (BST)
Clinical Development

Innovent and Takeda expand Phase III IBI363 lung cancer trial to non-squamous NSCLC

Announcement 28 Sep 2026 · 01:00:00 London (BST)

Published 28 Sep 2026 · 14:22:31 London (BST)
Licensing & Partnerships

Accuray and Samsung NeuroLogica pursue volumetric imaging integration for CyberKnife

Announcement 27 Sep 2026 · 16:15:00 London (BST)

Published 28 Sep 2026 · 14:22:31 London (BST)
Technology & Platform

Leo Cancer Care brings beam-agnostic upright radiotherapy platform into clinical use

Announcement 27 Sep 2026 (date only)

Published 28 Sep 2026 · 14:22:31 London (BST)

View all intelligence

The latest developments

Latest News

24 Sep 2026

Merck’s remigromig meets pivotal BRUNELLO endpoint in diabetic macular oedema

Merck has reported positive topline results from the pivotal Phase 2b/3 BRUNELLO trial of remigromig in diabetic macular oedema, with both tested doses meeting the study’s primary efficacy endpoint against the established anti-VEGF therapy ranibizumab. At 52…

Merck & Co.Aflibercept Bevacizumab

Read article

24 Sep 2026

FDA approves Lilly’s once-weekly Onswik basal insulin for adults with type 2 diabetes

The US Food and Drug Administration has approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, expanding the emerging US market for weekly background insulin. The FDA approval was granted on 23…

Eli Lilly and Company Insulin glargine Novo

Read article

24 Sep 2026

FDA advisers back GRAIL’s Galleri multi-cancer blood test in split effectiveness vote

A US Food and Drug Administration advisory committee has backed GRAIL’s Galleri blood test for screening people aged 50 and over for multiple cancers, moving the closely watched multi-cancer early detection technology another step towards possible FDA…

GRAIL

Read article

23 Sep 2026

Roche and Ionis sefaxersen meets Phase III proteinuria endpoint in IgA nephropathy

Roche and Ionis Pharmaceuticals have reported positive prespecified interim results from the Phase III IMAgINATION study of sefaxersen in adults with primary IgA nephropathy (IgAN), with the trial meeting its primary endpoint at 37 weeks. Sefaxersen produced a…

Roche Ionis Pharmaceuticals Iptacopan

Read article

22 Sep 2026

Anthropic and OpenEvidence launch global medical-AI collaboration for clinicians in around 100 countries

Anthropic and OpenEvidence have launched a collaboration to extend AI-powered clinical decision support to healthcare professionals across around 100 countries, with a particular focus on regions where access to current medical literature, specialist expertise…

Read article

21 Sep 2026

CagriSema outperforms tirzepatide 5 mg in diabetes trial

Novo has reported two new Phase III readouts for CagriSema, its once-weekly fixed-dose combination of the long-acting amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide. The headline result came from REIMAGINE 5, where CagriSema 1.0 mg/1.0…

Tirzepatide Cagrilintide Semaglutide

Read article

Read all news

Meet · Learn · Connect

Latest Events

Why Your Enrollment and Onboarding Costs More Than You Think

06 Oct 2026

Online

Why Your Enrollment and Onboarding Costs More Than You Think

Healthcare payers have added email, portals, digital ID cards, and new engagement channels to meet evolving member expectations. But layering these capabilities onto legacy enrollment and onboarding systems has also created increasingly complex operating environments.

View event

From Innovation to Market: How to Win in MedTech

14 Oct 2026

Barcelona, Spain

From Innovation to Market: How to Win in MedTech

We're excited to welcome Murat Akturk, Global Senior Director, Growth and Partnership at GE HealthCare, as a speaker at the 2nd MedTech Meets AI Conference in Barcelona! In his talk, "Innovation to Market and How to Win: 2 Case Studies in...

View event

From Data to Impact: Leveraging Tessie for AAV Process Development

21 Oct 2026

Online

From Data to Impact: Leveraging Tessie for AAV Process Development

As gene therapy development advances, increasing emphasis is being placed not only on viral vector yield but also on vector quality. A critical challenge in rAAV manufacturing is distinguishing vectors containing full-length therapeutic genomes from particles encapsidating truncated or partial genome fragments.

View event

View all events

Research & perspectives

Featured Resources

Information Brief · Available from 23 Sep 2026

Turning Gene Therapies into Patient Reality: Large Scale Cost-Effective AAV Production

Can AAV manufacturing scale without added cost or risk? As gene therapies expand beyond rare diseases and into larger patient populations, the industry faces a critical manufacturing question: can AAV production scale fast enough, affordably enough and reliably enough to support broader patient access?

View publication

eBook · Available from 17 Sep 2026

Molecular Cloning Workflow Solutions

This handbook provides best practices, product selection guidance, troubleshooting tips, and educational resources to help simplify cloning, transformation, sample preparation, electrophoresis, and gene synthesis—so you can move from clone to discovery with confidence.

View publication

eBook · Available from 17 Sep 2026

Prepare for Discovery - Molecular Biology Workflow Solutions

Inside this comprehensive 70-page handbook, you’ll find practical guidance and key considerations in sample preparation, reverse transcription, PCR, electrophoresis, cloning, isothermal amplification, and gene synthesis.

View publication

View all publications

Explore the intelligence behind the headlines

Follow the companies, drugs and diseases connected to industry developments.

Your weekly briefing

Subscribe to the Newsletter

Your weekly briefing, free to subscribe. Professional interests and preferences are optional.

Subscribe to the Newsletter

Professional opportunities

Choose job, consulting or partnership alerts, with optional private professional preferences.

About PHARMeMED

Connected intelligence for pharmaceutical and life sciences professionals.

PHARMeMED is a pharmaceutical and life sciences publishing and intelligence platform. It brings industry news together with connected information on companies, drugs, diseases, events and publications, helping professionals move from a development to the context around it.

Who PHARMeMED serves

PHARMeMED is designed for professionals working across pharmaceutical, biotechnology, medical technology and the wider life sciences ecosystem who need relevant developments and structured context in one place.

Connected intelligence

News is more useful when its context is visible. PHARMeMED connects reporting with company profiles, medicines, disease landscapes, industry events and professional publications.

Editorial mission

Our editorial mission is to make a complex industry easier to understand without reducing it to headlines or disconnected databases. We select developments for professional relevance and present them with clarity and restraint.

Editorial and technology approach

PHARMeMED uses editorially directed, AI-assisted workflows to support research, organisation and connections across the platform. Published material is human-reviewed. Technology supports the work; editorial judgement remains accountable for what appears on PHARMeMED.

Community context

PHARMeMED has grown in relationship with a LinkedIn community network of more than two million pharmaceutical and life sciences professionals. That community provides valuable context on the topics and professional needs that matter across the sector, while PHARMeMED maintains its own platform, editorial standards and direction.

Future direction and independence

PHARMeMED is developing as an independent industry publishing and intelligence platform. Editorial coverage is selected for relevance and value to readers. Commercial relationships and sponsored material should be clearly identified and should not determine editorial conclusions.

Weekly briefing

Subscribe to Newsletter

Weekly curation with no professional profile required.

Subscribe to Newsletter

Professional opportunities

Choose the newsletter, professional opportunities or both. Each choice is independent.

Profile review request

Submit Correction

Suggest updates to an existing company profile. Changes are reviewed before publication.

Current profile Company name Website LinkedIn URL Country Headquarters Company type Founded year Employee count Stock ticker Revenue Careers URL Logo URL Logo upload Contact name Contact email

Therapeutic areas

Focus Areas

Select relevant topics, technologies, capabilities or professional interests.

Products / Services Description Correction Notes

Discover what’s next in pharma, biotech and medtech.

Biopharma Markets

Lead News

Latest News

The week’s most important pharmaceutical developments.

Latest Events

Featured Resources

Explore the intelligence behind the headlines

Subscribe to the Newsletter

Subscribe

Subscribe to the PHARMeMED newsletter

A clearer view of the week

Who PHARMeMED serves

Connected intelligence

Editorial mission

Editorial and technology approach

Community context

Future direction and independence

Subscribe to Newsletter

Subscribe

Companies

Companies

Focus Areas

Submit Correction

News

Intelligence

Events

Publications

Latest Publications

Drugs

Drug Profiles are currently being added.

Explore disease intelligence

Subscribe to PHARMeMED

Privacy Policy

Terms of Use

Editorial & Information Disclaimer

Optional model cancellation form

Submit a Listing

Add or Claim a Company

Add Event

Add Publication

Add or Correct a Drug

Why claim your company?

Drug Submission

Select how you want to publish

Upload your event cover

Event Details

Event Details

Date and time

Attendance

Location

Availability

Description

Registration

Discoverability

Your Details

Payment

Add Publication

Add cover artwork Optional

Admin Panel

Admin Login

Site Settings

Promo Codes

Listing Submission Queue

Subscribers

Content Taxonomy

Taxonomy Groups

Add Taxonomy Group

Terms

Add Term

Aliases

Add Alias

Add Publication Category

Publication Categories

Add Publication Type

Publication Types

Add Therapeutic Area

Therapeutic Areas

Add Therapeutic Area Alias

Newsroom